Immune Recognition of Glycolipids
糖脂的免疫识别
基本信息
- 批准号:7329680
- 负责人:
- 金额:$ 53.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnti-Bacterial AgentsAntibacterial ResponseAntigen TargetingAntigen-Presenting CellsAntigensAutoimmunityBindingBiochemicalBiochemistryBiologicalCD1 AntigensCarrier ProteinsCellsCellular ImmunologyCellular biologyCeramidesChemicalsChemistryClassificationCollaborationsComplementComplexEffector CellElementsEvolutionFluorescence Resonance Energy TransferG(M2) Activator ProteinGalactosylceramidesGenetic PolymorphismGlycolipidsGoalsHeadHumanImmuneImmune systemIn VitroInflammationKnockout MiceKnowledgeLigand BindingLigandsLipid BindingLipidsLipoproteinsLysosomesMeasurementModificationMusMutagenesisNatureNumbersPathway interactionsPeptidesPhysiologyPopulationPrincipal InvestigatorProtein EngineeringProteinsPublicationsReactionRecombinant ProteinsRoleSAP-A ProteinShapesSolutionsStructureSurfaceSystemT-Cell ReceptorT-LymphocyteThermodynamicsThymus GlandTimeUrsidae FamilyVaccine AntigenWorkbasedesignexperienceextracellularimmunogenicin vivoisoglobotriaosylceramidelipid transfer proteinlipid transportoxidationparticleprogramsprotein expressionreceptorreconstitutionresearch studyresponseskillssuccesstraffickinguptake
项目摘要
The project entitled "Immune recognition of glycolipids" fits into a collaborative Program Project by
addressing biochemical and structural questions that complement biological studies led by Dr.Bendelac, and
by using extensively chemical compounds developed in collaboration with Dr.Savage. Our 3 Specific Aims
will be: Lipid Transfer Proteins (LTPs). We will examine the contribution of saposins A through D,
Niemann-Pick type C-2 and GM2 activator protein in the shaping of the repertoire of lipids presented by CD1
molecules in professional antigen presenting cells. In vivo studies in knock-out mice will evaluate the
contribution of each protein in the selection of NKT cells as well as in anti-bacterial responses. In vitro
studies will attempt to reconstitute the complex situation of the lysosome where CD1 resides with a mixture
of small LTPs and a wide spectrum of glycolipids. Biophysical measurements and structural studies will also
attempt to understand the mechanisms of transfer of lipids between CD1 and LTPs using real time FRET
and SPR. Extracellular Lipid Transport and Uptake. Extracellular lipids are kept in solution by associating
with lipoproteins particles or lipid transport proteins. The delivery of immunogenic lipids, such as bacterial
lipids, follows some of the same trafficking pathways. We will determine which pathway are important for
known agonists of NKT cells such as a-galactosyl ceramide (a-GalCer) and bacterial glucuronyl ceramides.
The identification of transport proteins will be driven by the usage of biotinylated compounds and
biochemistry. Lipid uptake and trafficking to the lysosome will be determined by cell biology and the usage of
knock-out mice for surface receptors. The consequences of in vivo modifications, such as oxidation that
accompanies inflammation, will also be studied with respect to transport. Finally, we will attempt some of the
knowledge gained by this specific aim to devise new strategies for delivering lipid antigens in vivo.
Structural Studies of CD1 recognition by Va14 T cell receptors. We know from experience that this
approach is highly unpredictable but we also know that it is unlikely that a sustained effort will not deliver
some results. This approach has allowed us to determine important structures such as CD1 bound to a-
GalCer but more structures are required. The main goal of this aim is to understand the ability of Va14 TCRs
to recognize ligands as different as CD1-iGb3 and CD1.-a-GalCer. To attain this goal new protein
engineering is required and will be exposed in details. Strong preliminary results will help us in the design of
these experiments. Additional CD1-lipid structures studies will also be proposed to understand the influence
of acyl chain unsaturation and head group modifications. Finally, we will also carry the systematic
mutagenesis of the Va14 chain to understand the thermodynamics of the reaction Va14/CD1.
题为“糖脂的免疫识别”的项目属于一个合作计划项目,
解决生物化学和结构问题,补充Bendelac博士领导的生物学研究,
通过广泛使用与萨维奇博士合作开发的化合物。我们的三个具体目标
将是:脂质转移蛋白(LTP)。我们将研究saposins A到D的作用,
Niemann-Pick C-2和GM 2激活蛋白在CD 1呈递的脂质库形成中的作用
专业抗原呈递细胞中的分子。在基因敲除小鼠中的体内研究将评估
每种蛋白质在NKT细胞的选择以及在抗细菌应答中的贡献。体外
研究将试图用混合物重建溶酶体的复杂情况,
小的LTP和广泛的糖脂。生物物理测量和结构研究也将
尝试使用真实的时间FRET来理解脂质在CD 1和LTP之间转移的机制
的SPR。细胞外脂质转运和摄取。细胞外脂质通过缔合而保持在溶液中
脂蛋白颗粒或脂质转运蛋白。免疫原性脂质,如细菌脂质的递送是有效的。
脂质遵循一些相同的运输途径。我们将确定哪些途径对
已知的NKT细胞激动剂如α-半乳糖基神经酰胺(α-GalCer)和细菌葡糖醛酸基神经酰胺。
转运蛋白的鉴定将通过使用生物素化的化合物来驱动,
生物化学脂质摄取和向溶酶体的运输将由细胞生物学和脂质代谢物的使用来确定。
表面受体基因敲除小鼠。体内修饰的后果,如氧化,
伴随炎症,也将研究关于运输。最后,我们将尝试一些
通过这一特定目标获得的知识设计用于体内递送脂质抗原的新策略。
Va 14 T细胞受体识别CD 1的结构研究。我们从经验中知道,
这种方法是高度不可预测的,但我们也知道,持续的努力不太可能不产生效果
一些结果。这种方法使我们能够确定重要的结构,如CD 1结合到一个-
但是需要更多的结构。该目的的主要目标是了解Va 14 TCR的能力,
识别与CD 1-iGb 3和CD 1-iGb 3不同的配体。α-GalCer。为了实现这一目标,
工程是必需的,并将在细节中暴露。强有力的初步结果将有助于我们设计
这些实验。还将提出额外的CD 1-脂质结构研究,以了解其影响
酰基链不饱和和头基修饰。最后,我们还将进行系统的
诱变的Va 14链,以了解反应Va 14/CD 1的热力学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Luc Teyton其他文献
Luc Teyton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Luc Teyton', 18)}}的其他基金
Molecular basis of glycan recognition by T and B cells
T 和 B 细胞识别聚糖的分子基础
- 批准号:
10549648 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D
利用人 iPSC 衍生的 β 细胞探测 T1D 中抗胰岛记忆 T 细胞的抗原特异性
- 批准号:
10589556 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10599324 - 财政年份:2021
- 资助金额:
$ 53.11万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10218993 - 财政年份:2021
- 资助金额:
$ 53.11万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10397167 - 财政年份:2021
- 资助金额:
$ 53.11万 - 项目类别:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
使用单细胞分析进行 1 型糖尿病的早期诊断和机制研究
- 批准号:
10362605 - 财政年份:2019
- 资助金额:
$ 53.11万 - 项目类别:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
使用单细胞分析进行 1 型糖尿病的早期诊断和机制研究
- 批准号:
9884757 - 财政年份:2019
- 资助金额:
$ 53.11万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 53.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 53.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 53.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




